<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000109" GROUP_ID="PREG" ID="769599081020085477" MERGED_FROM="" MODIFIED="2009-08-03 14:32:03 +0200" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Short title (no longer in use): Hormones for suspected impaired fetal growth&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-07-07 10:51:09 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0027" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2009-08-03 14:32:03 +0200" MODIFIED_BY="Sonja Henderson">
<TITLE>Hormones for suspected impaired fetal growth</TITLE>
<CONTACT MODIFIED="2009-08-03 14:32:03 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="13656" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lale</FIRST_NAME><LAST_NAME>Say</LAST_NAME><POSITION>Scientist, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)</POSITION><EMAIL_1>sayl@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 7914816</PHONE_1><FAX_1>+ 41 22 7914171</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-08-03 14:32:03 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="13656" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lale</FIRST_NAME><LAST_NAME>Say</LAST_NAME><POSITION>Scientist, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)</POSITION><EMAIL_1>sayl@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 7914816</PHONE_1><FAX_1>+ 41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="15905" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A Metin</FIRST_NAME><LAST_NAME>Gülmezoglu</LAST_NAME><POSITION>Scientist</POSITION><EMAIL_1>gulmezoglum@who.int</EMAIL_1><URL>http://www.who.int/reproductive-health/rhl/index.html</URL><ADDRESS><DEPARTMENT>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7913417</PHONE_1><FAX_1>+41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="15917" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>G Justus</FIRST_NAME><LAST_NAME>Hofmeyr</LAST_NAME><POSITION>Director/Hon. Professor, Effective Care Research Unit</POSITION><EMAIL_1>gjh@global.co.za</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology, East London Hospital Complex</DEPARTMENT><ORGANISATION>University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health</ORGANISATION><ADDRESS_1>Frere and Cecilia Makiwane Hospitals</ADDRESS_1><ADDRESS_2>Private Bag X 9047</ADDRESS_2><CITY>East London</CITY><ZIP>5200</ZIP><REGION>Eastern Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 43 7092483</PHONE_1><PHONE_2>+27 83 2809402</PHONE_2><FAX_1>+27 43 7092483</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-07-07 10:51:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 11/24/06&lt;/p&gt;&lt;p&gt;New studies sought but none found: 11/24/06&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 3/13/02&lt;/p&gt;&lt;p&gt;Reformatted: 8/11/99&lt;/p&gt;" NOTES_MODIFIED="2009-07-07 10:51:09 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="24" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="6" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="12" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1995"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1995"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2009-07-03 16:40:21 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-07-03 16:40:21 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated. No new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-06-24 11:49:06 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-06-24 11:49:06 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-21 12:09:43 +0100" MODIFIED_BY="Sonja Henderson">
<DATE DAY="24" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Search updated but no new trials identified.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-21 12:10:17 +0100" MODIFIED_BY="Sonja Henderson">
<DATE DAY="30" MONTH="6" YEAR="2004"/>
<DESCRIPTION>
<P>Search updated but no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-21 12:10:35 +0100" MODIFIED_BY="Sonja Henderson">
<DATE DAY="1" MONTH="11" YEAR="2002"/>
<DESCRIPTION>
<P>One study awaiting assessment was checked and excluded as it did not fulfil the criteria for the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>HRP - UNDP/UNFPA/WHO/World Bank Special Programme in Human Reproduction, Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Effective Care Research Unit, University of the Witwatersrand, East London/Johannesburg</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-07-03 16:49:07 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-03 14:13:23 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-03 14:13:08 +0100" MODIFIED_BY="[Empty name]">Hormones for suspected impaired fetal growth</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-03 14:13:23 +0100" MODIFIED_BY="[Empty name]">
<P>No evidence to show whether the unborn baby's growth improves when pregnant women take extra oestrogen.</P>
<P>Babies in the womb growing more slowly than expected (impaired fetal growth) may be receiving too few nutrients from their mother's blood. Hormones are chemicals produced by glands in the body for growth, metabolism (how the body uses food) and reproduction. Oestrogen (the female hormone) is thought to increase blood flow from pregnant women to their babies, thus potentially providing more nutrients. The review of trials has found no evidence to show whether the baby's growth improves when pregnant women take extra oestrogen. There is no evidence from trials on the effects of oestrogen supplementation on women and their babies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-06-24 11:49:31 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>It has been suggested that oestrogens may improve fetal growth due to an increase in nutritional supply to the fetus from greater uterine blood flow. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the effects of hormone administration for suspected impaired fetal growth and perinatal outcome.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-06-24 11:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2009).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Acceptably controlled trials of hormone administration for suspected impaired fetal growth which report fetal, perinatal or maternal outcomes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Eligibility and trial quality were assessed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No studies were included since none of the potentially relevant trials reported clinical outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is not enough evidence to evaluate the clinical use of hormone administration for suspected impaired fetal growth.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-07-03 16:49:07 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-07-03 16:49:07 +0100" MODIFIED_BY="[Empty name]">
<P>Impaired fetal growth is the failure of a newborn to achieve its genetically determined growth potential, which may cause death as well as short or long-term childhood morbidity. It has been reported that 3% to 10% of neonates are small for corresponding gestational age and an estimated 30% of this is due to impaired fetal growth. Remaining 70% is due to constitutional factors such as maternal ethnicity, parity, weight and height (<LINK REF="REF-Lin-1998" TYPE="REFERENCE">Lin 1998</LINK>). The condition occurs with limited flow of nutrients or oxygen, or both, from mother to fetus as a result of fetal causes (e.g. chromosomal abnormalities, congenital malformations), placental factors (e.g. small placenta), or maternal factors (e.g. malnutrition, vascular/renal disease, drugs or other metabolic conditions) (<LINK REF="REF-Resnik-2002" TYPE="REFERENCE">Resnik 2002</LINK>).</P>
<P>Ultrasound evaluation of the fetus by measuring the abdominal circumference, head circumference, length of upper leg and interpreting these using standardised formulae allows the clinician to estimate the fetal weight, to relate this to the gestational age and to follow the growth progress. Ultrasound evaluation also allows to some extent to estimate the timing and the cause of the impairment. Symmetrical growth of the fetus is generally due to early problems such as chromosomal abnormalities, drugs, chemical agents or infection. Asymmetric growth usually results from inadequacy of substrates the fetus needs particularly later in pregnancy (<LINK REF="REF-Resnik-2002" TYPE="REFERENCE">Resnik 2002</LINK>). In low-income settings where early pregnancy ultrasound is not available fetal growth can be monitored by serial symphysis fundus measurements. However, there is no proven effective treatment that can be applied once growth impairment is diagnosed. In general, when no apparent congenital abnormality exists, management is conservative by frequent growth measurements, smoking cessation if the mother smokes and early delivery when the fetus is thought be mature enough to survive outside the womb.</P>
<P>The outcomes of impaired growth are variable and usually related to the specific cause. For example, if the growth impairment is due to chromosomal anomalies or congenital abnormalities, the fetus is more at risk of a perinatal death. Other short-term outcomes may be moderate to mild metabolic problems (hypoglycemia, polycythemia, meconium aspiration, etc.) due to the chronic oxygen and nutrient deprivation. Depending on the severity and the duration of the condition, long-term outcomes may differ from normal to small decreases in IQ to an increased risk of cerebral palsy (<LINK REF="REF-Bernstein-2000" TYPE="REFERENCE">Bernstein 2000</LINK>).</P>
<P>It has been suggested and shown with some animal studies (<LINK REF="REF-Greiss-1970" TYPE="REFERENCE">Greiss 1970</LINK>; <LINK REF="REF-Killam-1973" TYPE="REFERENCE">Killam 1973</LINK>) that oestrogens could increase the nutritional supply to the fetus because of an increase in uterine blood flow. This increase could theoretically improve the outcome of fetuses with growth impairment due to restricted blood flow to the placenta.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects on fetal growth and perinatal outcome of hormone administration for suspected impaired fetal growth.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-06-24 11:50:05 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All acceptably controlled evaluations of hormone administration for suspected impaired fetal growth.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women with suspected impaired fetal growth.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Hormones administered during pregnancy to promote fetal growth.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Perinatal death, neonatal morbidity, fetal growth, adverse effects on the mother and neonate.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-06-24 11:50:05 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-06-24 11:50:05 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (June 2009). </P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.  </P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Trials under consideration were evaluated for methodological quality and appropriateness for inclusion, without consideration of their results. Included trial data were processed as described in <LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>None of the four studies found were randomised and all are excluded from the review (<I>see</I> 'References to studies; excluded studies').</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Not applicable.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>None.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>
<I>See</I> 'Implications'.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Based on the evidence examined for this review, there is no evidence whether the clinical use of hormones for suspected impairment of fetal growth is effective.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>In view of evidence from animal studies of a positive effect of oestrogens on uterine blood flow, investigation of their effectiveness for suspected impaired fetal growth would seem justified.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Justus Hofmeyr wrote the original review for the Cochrane Pregnancy and Childbirth Database. Metin Gülmezoglu updated the review, and has been responsible for maintaining the review since 1995. Both review authors did the data extraction and contributed to the text of the review. Lale Say contributed to the recent update by checking the data entries and revising the text of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-06-24 11:50:37 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Grunberger-1981" NAME="Grunberger 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Grunberger W, Parschalk O, Fischl F. Treatment of hypotension complicating pregnancy improves fetal outcome (translation). Medizinische Klinik 1981;76:257-60&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grunberger W, Parschalk O, Fischl F</AU>
<TI>Treatment of hypotension complicating pregnancy improves fetal outcome</TI>
<SO>Medizinische Klinik</SO>
<YR>1981</YR>
<VL>76</VL>
<PG>257-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niven-1974" NAME="Niven 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;[960]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niven PAR, Buhi WC, Spellacy WN</AU>
<TI>The effect of intravenous oestrogen injections on plasma human placental lactogen levels</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1974</YR>
<VL>81</VL>
<PG>466-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearce-1988" NAME="Pearce 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;[4523]&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pearce JM, McParland P, Steel SA, Huiskes N</AU>
<TI>Effect of allyloestrenol on deteriorating uteroplacental circulation</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>2</VL>
<PG>1252</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;10415&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pearce JM, Steel SA</AU>
<TI>A double blind placebo controlled pilot study on the effects of allylestrenol on flow velocity wave forms from the uteroplacental and fetal circulation</TI>
<SO>World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil</SO>
<YR>1988</YR>
<PG>249</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thoumsin-1975" NAME="Thoumsin 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;[1077]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thoumsin H, Lambotte R</AU>
<TI>Therapeutic possibilities of dehydroepiandrosterone in foetal hypotrophy</TI>
<SO>Annales d' Endocrinologie (Paris)</SO>
<YR>1975</YR>
<VL>36</VL>
<PG>113-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-06-24 11:50:37 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bernstein-2000" NAME="Bernstein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A</AU>
<TI>Morbidity and mortality among very low birth weight infants with intrauterine growth restriction. The Vermont Oxford Network</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>182</VL>
<PG>198</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M Oxman AD, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.1 [updated June 2000]</TI>
<SO>In: Review Manager (RevMan) [Computer program]. Version 4.1 Oxford, England: The Cochrane Collaboration, 2000</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greiss-1970" NAME="Greiss 1970" TYPE="JOURNAL_ARTICLE">
<AU>Greiss FC, Anderson SG</AU>
<TI>Effect of ovarian hormones on the uterine vascular bed</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1970</YR>
<VL>107</VL>
<PG>829</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Killam-1973" NAME="Killam 1973" TYPE="JOURNAL_ARTICLE">
<AU>Killam AP, Rosenfeld CR, Battaglia FC, Makowski EL, Meschia G</AU>
<TI>Effect of estrogens on the uterine blood flow of oophorectomized ewes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1973</YR>
<VL>115</VL>
<PG>1045</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-1998" NAME="Lin 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lin C, Santolaya-Forgas J</AU>
<TI>Current concepts of fetal growth restriction: Part 1. Causes, classification, and pathophysiology</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>6</NO>
<PG>1044-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Resnik-2002" NAME="Resnik 2002" TYPE="JOURNAL_ARTICLE">
<AU>Resnik R</AU>
<TI>Intrauterine growth restriction</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>3</NO>
<PG>490-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-06-24 11:50:37 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-G_x00fc_lmezoglu-2002" MODIFIED="2009-06-24 11:50:37 +0100" MODIFIED_BY="[Empty name]" NAME="Gülmezoglu 2002" TYPE="COCHRANE_REVIEW">
<AU>Gülmezoglu AM, Hofmeyr GJ</AU>
<TI>Hormones for suspected impaired fetal growth</TI>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Grunberger-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a comparative study of mineralocorticoid treatment for pregnant women with low blood pressure. The study is not a randomised trial and the treatment of hypotensive women is outside the scope of this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niven-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinically relevant outcomes are available. Intravenous conjugated oestrogens had no measurable effect on plasma human placental lactogen levels.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pearce-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No adequate data are available. Allyloestrenol for ultrasonically-diagnosed impaired fetal growth appeared to inhibit an increase in uteroplacental doppler resistance index (6 study participants and 5 controls).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thoumsin-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No adequate data are available. Intravenous dehydroepiandrosterone sulphate had no measurable effect on 24-hour oestriol excretion, plasma human placental lactogen levels or biparietal diameter changes. 'Uterine growth' appeared to be increased.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>